

Thomas A Waldmann

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9336275/thomas-a-waldmann-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

433
papers

40,620
citations

107
h-index

188
g-index

458
ext. papers

43,751
ext. citations

11.8
avg, IF

7.28
L-index

#	Paper	IF	Citations
433	Triple combination of BET plus PI3K and NF- κ B inhibitors exhibit synergistic activity in adult T cell leukemia/lymphoma.. <i>Blood Advances</i> , 2022 ,	7.8	1
432	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors 2021 , 9,		2
431	IL-15 -Presentation Is an Autonomous, Antigen-Independent Process. <i>Journal of Immunology</i> , 2021 , 207, 2489-2500	5.3	1
430	A novel model of alternative NF- κ B pathway activation in anaplastic large cell lymphoma. <i>Leukemia</i> , 2021 , 35, 1976-1989	10.7	1
429	NF- κ B-induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	7
428	Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies 2021 , 9,		6
427	Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance. <i>Frontiers in Immunology</i> , 2021 , 12, 657293	8.4	4
426	EGR1 Addiction in Diffuse Large B-cell Lymphoma. <i>Molecular Cancer Research</i> , 2021 , 19, 1258-1269	6.6	0
425	Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases. <i>Molecular Cancer</i> , 2021 , 20, 86	42.1	3
424	Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice. <i>Journal of Immunology</i> , 2021 , 207, 1194-1199	5.3	0
423	Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. <i>Translational Oncology</i> , 2021 , 14, 100913	4.9	3
422	IL-15 in the Combination Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2020 , 11, 868	8.4	48
421	NK cells prevent T cell lymphoma development in T cell receptor-transgenic mice. <i>Cellular Immunology</i> , 2020 , 352, 104081	4.4	3
420	Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 23-24	2.2	2
419	Results From a First-in-Human Study of BNZ-1, a Selective Multicytokine Inhibitor Targeting Members of the Common Gamma (γ) Family of Cytokines. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 264-273	2.9	7
418	-endocytosis of intact IL-15R β L-15 complex from presenting cells into NK cells favors signaling for proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 522-531	11.5	19
417	Engagement of lymphoma T cell receptors causes accelerated growth and the secretion of an NK cell-inhibitory factor. <i>Cellular Immunology</i> , 2020 , 357, 104213	4.4	1

416	Analysis of Human Natural Killer Cell Metabolism. <i>Journal of Visualized Experiments</i> , 2020 ,	1.6	3
415	Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 28980-28991	11.5	4
414	Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	33
413	Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink. <i>Frontiers in Immunology</i> , 2020 , 11, 1813	8.4	3
412	Identification of a β Receptor Antagonist That Prevents Reprogramming of Human Tissue-resident Cytotoxic T Cells by IL15 and IL21. <i>Gastroenterology</i> , 2020 , 158, 625-637.e13	13.3	13
411	Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin Θ Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020 , 35, 219-224	3.9	7
410	A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models. <i>Clinical Cancer Research</i> , 2020 , 26, 4093-4106	12.9	11
409	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. <i>Blood</i> , 2019 , 134, 1406-1414	2.2	50
408	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. <i>Journal of Clinical Oncology</i> , 2019 , 37, 677-687	2.2	94
407	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. <i>Clinical Cancer Research</i> , 2019 , 25, 4945-4954	12.9	47
406	Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1437-1448	4.9	7
405	Cytokines in the Treatment of Cancer. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 6-21	3.5	144
404	Clinical trial of a humanized anti-IL-2/IL-15 receptor β chain in HAM/TSP. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1383-1394	5.3	5
403	IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2R β therapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 21120-21130	11.5	14
402	Blockade of IL-15 Utilizing Bnz-1, a Selective β Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial. <i>Blood</i> , 2019 , 134, 2835-2835	2.2	5
401	Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies. <i>Blood</i> , 2019 , 134, 1558-1558	2.2	
400	Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2019 , 134, 3781-3781	2.2	
399	Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019 , 134, 3052-3052	2.2	

398	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. <i>Blood Advances</i> , 2019 , 3, 1970-1980	7.8	90
397	Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2062-2066	1.9	5
396	IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective Echain cytokines, decreases leukemic T-cell viability. <i>Leukemia</i> , 2019 , 33, 1243-1255	10.7	23
395	Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E498-E505	11.5	43
394	Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1466-1469	1.9	6
393	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. <i>Cancer Cell</i> , 2018 , 34, 286-297.e10	24.3	44
392	Membrane Potential Distinctly Modulates Mobility and Signaling of IL-2 and IL-15 Receptors in T Cells. <i>Biophysical Journal</i> , 2018 , 114, 2473-2482	2.9	6
391	Protection by universal influenza vaccine is mediated by memory CD4 T cells. <i>Vaccine</i> , 2018 , 36, 4198-4206	11.6	18
390	Cytokines in Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018 , 10,	10.2	173
389	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 1525-1535	12.9	95
388	Minimum degree of overlap between IL-9R and IL-2R on human T lymphoma cells: A quantitative CLSM and FRET analysis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018 , 93, 1106-1117	4.6	5
387	IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E10915-E10924	11.5	60
386	Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. <i>New England Journal of Medicine</i> , 2018 , 378, 1947-1948	59.2	122
385	JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. <i>Molecular and Cellular Endocrinology</i> , 2017 , 451, 66-70	4.4	18
384	Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. <i>Annual Review of Immunology</i> , 2017 , 35, 533-550	34.7	87
383	Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. <i>American Journal of Hematology</i> , 2017 , 92, 892-901	7.1	43
382	Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 3975-3980	11.5	42
381	IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56 NK Cells and Increases NK-Cell Cytokine Release Capabilities. <i>Cancer Immunology Research</i> , 2017 , 5, 929-938	12.5	47

380	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 35-42	12.9	24
379	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. <i>Clinical Cancer Research</i> , 2016 , 22, 310-8	12.9	42
378	MHC I Expression Regulates Co-clustering and Mobility of Interleukin-2 and -15 Receptors in T Cells. <i>Biophysical Journal</i> , 2016 , 111, 100-12	2.9	13
377	Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia. <i>Molecular Cancer</i> , 2016 , 15, 15	42.1	19
376	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E2039-46	11.5	38
375	Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1624-9	11.5	30
374	Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells. <i>Blood</i> , 2016 , 128, 503-503	2.2	1
373	The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. <i>Cancer Immunology Research</i> , 2015 , 3, 219-27	12.5	114
372	Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. <i>Immunity</i> , 2015 , 42, 826-38	32.3	100
371	Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 12480-5	11.5	58
370	90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 13045-50	11.5	37
369	Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS). <i>Journal of Clinical Immunology</i> , 2015 , 35, 661-7	5.7	8
368	IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. <i>Cancer Research</i> , 2015 , 75, 5187-5193	10.1	56
367	Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 74-82	2.2	394
366	Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model. <i>Leukemia</i> , 2015 , 29, 556-66	10.7	21
365	A gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the chemotactic abilities and P13K/AKT activation. <i>Retrovirology</i> , 2015 , 12,	3.6	78
364	Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. <i>Retrovirology</i> , 2015 , 12,	3.6	2
363	IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma. <i>American Journal of Pathology</i> , 2015 , 185, 3102-14	5.8	21

362	Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes. <i>PLoS ONE</i> , 2015 , 10, e0143001	3.7	8
361	miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic β cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 476-81	11.5	80
360	Abstract 1332: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20 2015 ,		3
359	Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein. <i>PLoS ONE</i> , 2015 , 10, e0141141	3.7	0
358	IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 5676-81	11.5	34
357	Vaccination with tumor cells expressing IL-15 and IL-15R β inhibits murine breast and prostate cancer. <i>Gene Therapy</i> , 2014 , 21, 393-401	4	25
356	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. <i>Clinical Immunology</i> , 2014 , 155, 176-87	9	51
355	Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia. <i>Retrovirology</i> , 2014 , 11, 43	3.6	9
354	Distinct spatial relationship of the interleukin-9 receptor with interleukin-2 receptor and major histocompatibility complex glycoproteins in human T lymphoma cells. <i>ChemPhysChem</i> , 2014 , 15, 3969-78 ^{3.2}		9
353	A new domain in the Toll/IL-1R domain-containing adaptor inducing interferon- β factor protein amino terminus is important for tumor necrosis factor- β receptor-associated factor 3 association, protein stabilization and interferon signaling. <i>Journal of Innate Immunity</i> , 2014 , 6, 377-93	6.9	5
352	Interleukin-15 in the treatment of cancer. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 1689-701	5.1	51
351	Frequent STAT5B mutations in hepato-splenic T-cell lymphomas. <i>Leukemia</i> , 2014 , 28, 2244-8	10.7	95
350	Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. <i>Journal of Experimental Medicine</i> , 2014 , 211, 2497-505	16.6	105
349	IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells. <i>European Journal of Immunology</i> , 2014 , 44, 3330-41	6.1	30
348	Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. <i>OncImmunology</i> , 2014 , 3, e959321	7.2	14
347	Loss of cytotoxicity and gain of cytokine production in murine tumor-activated NK cells. <i>PLoS ONE</i> , 2014 , 9, e102793	3.7	6
346	A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation. <i>Blood</i> , 2014 , 124, 3566-3566	2.2	
345	Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. <i>Journal of Clinical Immunology</i> , 2013 , 33, 586-94 ^{5.7}		43

344	Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. <i>Blood</i> , 2013 , 121, 5045-54	2.2	30
343	The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2013 , 16, S28-30	1.1	64
342	GVL for ATL?. <i>Blood</i> , 2013 , 121, 6-7	2.2	3
341	Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 1841-8	4.4	5
340	Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15R β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 13534-9	11.5	50
339	Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. <i>Blood</i> , 2013 , 121, 2029-37	2.2	32
338	Phase 1 trial of IL-15 trans presentation blockade using humanized Mik1 mAb in patients with T-cell large granular lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 476-84	2.2	46
337	Superior T memory stem cell persistence supports long-lived T cell memory. <i>Journal of Clinical Investigation</i> , 2013 , 123, 594-9	15.9	216
336	Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. <i>Blood</i> , 2012 , 120, 1816-9	2.2	13
335	Interleukin-15 biology and its therapeutic implications in cancer. <i>Trends in Pharmacological Sciences</i> , 2012 , 33, 35-41	13.2	246
334	The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. <i>Microbes and Infection</i> , 2012 , 14, 247-61	9.3	98
333	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012 , 490, 116-20	50.4	600
332	Increased serum soluble IL-15R α levels in T-cell large granular lymphocyte leukemia. <i>Blood</i> , 2012 , 119, 137-43	2.2	45
331	Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in <i>E. coli</i> with stop codon optimization. <i>Biotechnology Progress</i> , 2012 , 28, 497-507 ^{2.8}	2.8	11
330	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2012 , 21, 723-37	24.3	386
329	Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15R α in human monocytes and dendritic cells. <i>Journal of Biological Chemistry</i> , 2012 , 287, 40328-38	5.4	16
328	Selective dependence of H2-M3-restricted CD8 responses on IL-15. <i>Journal of Immunology</i> , 2012 , 188, 2575-82	5.3	2
327	Augmented IL-15R α expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. <i>Journal of Immunology</i> , 2012 , 188, 6156-64	5.3	38

326	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 6187-92	11.5	77
325	Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML. <i>Blood</i> , 2012 , 120, 894-894	2.2	9
324	Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15R β . <i>Blood</i> , 2011 , 117, 4032-40	2.2	26
323	IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. <i>Blood</i> , 2011 , 118, 6845-8	2.2	62
322	CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. <i>Blood</i> , 2011 , 117, 1938-46	2.2	58
321	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. <i>Blood</i> , 2011 , 117, 4787-95	2.2	127
320	FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2011 , 118, 3911-21	2.2	72
319	Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. <i>EMBO Journal</i> , 2011 , 30, 627-627	13	1
318	Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. <i>Nature</i> , 2011 , 471, 220-4	50.4	306
317	A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. <i>Nature Medicine</i> , 2011 , 17, 604-9	50.5	207
316	Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy. <i>Blood</i> , 2011 , 118, 2575-2575	2.2	3
315	Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. <i>Vaccine Journal</i> , 2010 , 17, 793-801		38
314	Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 18091-6	11.5	21
313	Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 16619-24	11.5	71
312	Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. <i>Clinical Cancer Research</i> , 2010 , 16, 6019-28	12.9	144
311	Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. <i>Cancer Research</i> , 2010 , 70, 1072-81	10.1	39
310	Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys. <i>Vaccine</i> , 2010 , 28, 7081-91	4.1	14
309	Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. <i>Blood</i> , 2010 , 116, 3238-48	2.2	85

308	Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. <i>Blood</i> , 2010 , 116, 5948-56	2.2	31
307	EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. <i>Clinical Cancer Research</i> , 2009 , 15, 2514-22	12.9	48
306	Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 7513-8	11.5	107
305	Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. <i>Journal of Immunology</i> , 2009 , 182, 3063-71	5.3	51
304	Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009 , 24, 303-9	3.9	2
303	Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. <i>Human Gene Therapy</i> , 2009 , 20, 1143-56	4.8	20
302	Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 483-9		142
301	Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 15849-54	11.5	96
300	Antibody-based therapy of leukaemia. <i>Expert Reviews in Molecular Medicine</i> , 2009 , 11, e29	6.7	29
299	MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. <i>Journal of Immunological Methods</i> , 2009 , 348, 83-94	2.5	30
298	A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. <i>Vaccine</i> , 2009 , 27, 2121-7	4.1	21
297	Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. <i>Blood</i> , 2009 , 113, 1287-93	2.2	34
296	Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. <i>Blood</i> , 2009 , 113, 4016-26	2.2	59
295	Cardiac involvement with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience. <i>Leukemia and Lymphoma</i> , 2008 , 49, 439-46	1.9	9
294	High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. <i>Journal of Autoimmunity</i> , 2008 , 31, 91-7	15.5	76
293	Receptor-directed therapy of T-cell leukemias and lymphomas. <i>Journal of Immunotoxicology</i> , 2008 , 5, 235-48	3.1	17
292	IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells. <i>Journal of Immunology</i> , 2008 , 180, 7276-86	5.3	18
291	Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cells. <i>Journal of Cell Science</i> , 2008 , 121, 627-33	5.3	56

290	IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 5201-6	11.5	117
289	Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. <i>Journal of Immunology</i> , 2008 , 180, 2099-106	5.3	157
288	IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease. <i>Journal of Immunology</i> , 2008 , 181, 1109-19	5.3	19
287	Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. <i>Clinical Cancer Research</i> , 2008 , 14, 875-82	12.9	47
286	Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. <i>Blood</i> , 2008 , 111, 5163-72	2.2	45
285	Sustained suppression of SHIV89.6P replication in macaques by vaccine-induced CD8+ memory T cells. <i>Aids</i> , 2008 , 22, 1739-48	3.5	8
284	A novel solid phase technology for high-throughput gene synthesis. <i>BioTechniques</i> , 2008 , 45, 340-3	2.5	55
283	A biophysical approach to IL-2 and IL-15 receptor function: localization, conformation and interactions. <i>Immunology Letters</i> , 2008 , 116, 117-25	4.1	38
282	Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.. <i>Blood</i> , 2008 , 112, 2010-2010	2.2	1
281	A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet disease. <i>Ocular Immunology and Inflammation</i> , 2007 , 15, 63-70	2.8	85
280	Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. <i>Oncogene</i> , 2007 , 26, 3699-703	9.2	72
279	Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. <i>Journal of Clinical Immunology</i> , 2007 , 27, 1-18	5.7	119
278	Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. <i>Journal of Virology</i> , 2007 , 81, 8774-83	6.6	35
277	The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 588-93	11.5	137
276	A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. <i>Clinical Cancer Research</i> , 2007 , 13, 958-64	12.9	143
275	Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 8444-8	11.5	32
274	Colorectal carcinoma rearranges cell surface protein topology and density in CD4+ T cells. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 361, 202-7	3.4	14
273	Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 18648-53	11.5	80

272	The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. <i>Cancer Research</i> , 2006 , 66, 8227-32	10.1	40
271	Development of antibodies and chimeric molecules for cancer immunotherapy. <i>Advances in Immunology</i> , 2006 , 90, 83-131	5.6	36
270	Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 401-6	11.5	60
269	Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 5084-9	11.5	127
268	ITK and IL-15 support two distinct subsets of CD8+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 12075-80	11.5	78
267	Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2/Ralpha-targeted therapy (daclizumab) in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 5941-6	11.5	481
266	Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. <i>Blood</i> , 2006 , 108, 1021-9	2.2	118
265	Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein. <i>Nuclear Medicine and Biology</i> , 2006 , 33, 469-80	2.1	16
264	Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. <i>Blood</i> , 2006 , 108, 705-10	2.2	30
263	Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. <i>Blood</i> , 2006 , 108, 1007-12	2.2	32
262	The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. <i>Nature Reviews Immunology</i> , 2006 , 6, 595-601	36.5	800
261	Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. <i>Leukemia Research</i> , 2006 , 30, 190-203	2.7	34
260	Effective cancer therapy through immunomodulation. <i>Annual Review of Medicine</i> , 2006 , 57, 65-81	17.4	68
259	Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinium-labeled dendrimer nanoparticle. <i>Neoplasia</i> , 2005 , 7, 984-91	6.4	47
258	Transmembrane Signals Mediated by IL-2 and IL-15 Control the Life and Death of Lymphocytes 2005 , 97-121		2
257	Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. <i>Blood</i> , 2005 , 105, 721-7	2.2	202
256	Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. <i>Blood</i> , 2005 , 105, 1231-6	2.2	29
255	Detection of receptor trimers on the cell surface by flow cytometric fluorescence energy homotransfer measurements. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005 , 1744, 176-98 ^{4.9}		10

254	Detection of channel proximity by nanoparticle-assisted delaying of toxin binding; a combined patch-clamp and flow cytometric energy transfer study. <i>European Biophysics Journal</i> , 2005 , 34, 127-43	1.9	5
253	Survival adjustment of mature dendritic cells by IL-15. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 8662-7	11.5	69
252	Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. <i>Journal of Immunology</i> , 2005 , 175, 112-23	5.3	164
251	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 9571-6	11.5	692
250	Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. <i>Clinical Cancer Research</i> , 2004 , 10, 7712-20	12.9	71
249	Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. <i>Cancer Research</i> , 2004 , 64, 5825-9	10.1	57
248	Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. <i>Cancer Research</i> , 2004 , 64, 1460-7	10.1	58
247	Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N'N",N"Q tetraacetic acid-biotin. <i>Clinical Cancer Research</i> , 2004 , 10, 3137-46	12.9	36
246	IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 11082-7	11.5	107
245	IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 1969-74	11.5	441
244	IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 15154-9	11.5	113
243	Micro-MRI methods to detect renal cysts in mice. <i>Kidney International</i> , 2004 , 65, 1511-6	9.9	23
242	Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 703-8	9.7	131
241	Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 8705-8	11.5	295
240	Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. <i>Arthritis Research</i> , 2004 , 6, 174-7		49
239	Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. <i>Nuclear Medicine and Biology</i> , 2004 , 31, 357-64	2.1	16
238	Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins. <i>Nuclear Medicine and Biology</i> , 2004 , 31, 1061-71	2.1	16
237	Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. <i>Blood</i> , 2004 , 104, 3355-7	2.2	46

236	Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 14169-74	11.5	34
235	Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 2592-7	11.5	76
234	ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S107-13	1.9	15
233	The meandering 45-year odyssey of a clinical immunologist. <i>Annual Review of Immunology</i> , 2003 , 21, 1-27	34.7	12
232	Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. <i>Blood</i> , 2003 , 102, 284-8	2.2	60
231	Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. <i>Magnetic Resonance in Medicine</i> , 2003 , 50, 758-66	4.4	97
230	Immunotherapy: past, present and future. <i>Nature Medicine</i> , 2003 , 9, 269-77	50.5	455
229	Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase. <i>Bioconjugate Chemistry</i> , 2003 , 14, 1044-7	6.3	30
228	Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8053-8	11.5	421
227	IL-15 in the life and death of lymphocytes: immunotherapeutic implications. <i>Trends in Molecular Medicine</i> , 2003 , 9, 517-21	11.5	42
226	A novel means of favorably tipping the balance between cytopathic and regulatory T cells. <i>Immunity</i> , 2003 , 19, 465-6	32.3	3
225	Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. <i>Journal of Autoimmunity</i> , 2003 , 21, 283-93	15.5	110
224	Interleukin-2 receptor-directed therapies for cutaneous lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2003 , 17, 1449-58	3.1	19
223	Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 1891-5	11.5	89
222	Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 3392-7	11.5	160
221	Interleukin-15 2003 , 478-484		1
220	Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. <i>Cancer Research</i> , 2003 , 63, 271-6	10.1	86
219	Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. <i>Cancer Research</i> , 2003 , 63, 6453-7	10.1	79

218	GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell lines. <i>FEBS Journal</i> , 2002 , 269, 1199-208		72
217	The IL-2/IL-15 receptor systems: targets for immunotherapy. <i>Journal of Clinical Immunology</i> , 2002 , 22, 51-6	5.7	75
216	Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. <i>Journal of Immunology</i> , 2002 , 169, 3120-30	5.3	46
215	Viral Activation of Interleukin-15 (IL-15): Characterization of a Virus-Inducible Element in the IL-15 Promoter Region. <i>Journal of Virology</i> , 2002 , 76, 6864-6864	6.6	78
214	IFN regulatory factor 4 participates in the human T cell lymphotropic virus type I-mediated activation of the IL-15 receptor alpha promoter. <i>Journal of Immunology</i> , 2002 , 168, 5667-74	5.3	22
213	Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. <i>Blood</i> , 2002 , 100, 208-16	2.2	95
212	Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates. <i>Bioconjugate Chemistry</i> , 2002 , 13, 786-91	6.3	11
211	Oligomerization of IL-2Ralpha. <i>Cytokine</i> , 2002 , 17, 82-90	4	18
210	The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. <i>Arthritis Research</i> , 2002 , 4 Suppl 3, S161-7		62
209	IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. <i>Immunity</i> , 2002 , 17, 537-47	32.3	703
208	Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications. <i>Nuclear Medicine and Biology</i> , 2002 , 29, 139-46	2.1	13
207	The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. 1976. <i>Journal of Urology</i> , 2002 , 167, 934-7; discussion 938	2.5	1
206	Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. <i>Cancer Research</i> , 2002 , 62, 1083-6	10.1	98
205	Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N,N",N"tetraacetic acid (DOTA)-biotin. <i>Cancer Research</i> , 2002 , 62, 5755-60	10.1	24
204	Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 7970-5	11.5	86
203	IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 14559-64	11.5	52
202	Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 5146-51	11.5	29
201	Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. <i>Journal of Immunology</i> , 2001 , 166, 2602-9	5.3	79

200	Clustering of class I HLA oligomers with CD8 and TCR: three-dimensional models based on fluorescence resonance energy transfer and crystallographic data. <i>Journal of Immunology</i> , 2001 , 166, 5078-86	5.3	36
199	Differential effects of IL-2 and IL-15 on expression of IL-2 receptor alpha. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 285, 1302-8	3.4	15
198	Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. <i>Nuclear Medicine and Biology</i> , 2001 , 28, 845-56	2.1	34
197	Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes. <i>Immunity</i> , 2001 , 14, 105-110	32.3	65
196	The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2001 , 40, 287-94	1.9	59
195	Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1622-36	2.2	379
194	Synthesis and biodistribution study of a new 211At-calix[4]arene complex. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2000 , 43, 1219-1225	1.9	14
193	Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000 , 10, 1025-8	2.9	12
192	p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF/MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. <i>Blood</i> , 2000 , 95, 3939-3944	2.2	54
191	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 394-408	3.1	23
190	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 394-408	3.1	6
189	The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15. <i>Journal of Biological Chemistry</i> , 2000 , 275, 30653-9	5.4	82
188	IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 11445-50	11.5	341
187	Deletion of the p16INK4A gene in ex vivo acute adult T cell lymphoma/leukemia cells and methylation of the p16INK4A promoter in HTLV type I-infected T cell lines. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 709-13	1.6	19
186	How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis?. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 1717-22	1.6	20
185	Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 6013-8	11.5	140
184	Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. <i>Journal of Virology</i> , 2000 , 74, 7338-48	6.6	61
183	Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1573-81	9.7	37

182	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 394-408	3.1	1
181	p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF/MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. <i>Blood</i> , 2000 , 95, 3939-3944	2.2	22
180	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. <i>Blood</i> , 1999 , 94, 3340-3348.	2.2	145
179	Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 7462-6	11.5	265
178	The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. <i>Annual Review of Immunology</i> , 1999 , 17, 19-49	34.7	592
177	Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2. <i>Cytokine</i> , 1999 , 11, 1065-75	4	15
176	Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. <i>Nature</i> , 1998 , 391, 700-3	50.4	303
175	Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen. <i>Japanese Journal of Cancer Research</i> , 1998 , 89, 436-44		1
174	Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody. <i>Leukemia</i> , 1998 , 12, 982-91	10.7	4
173	Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. <i>Annals of Neurology</i> , 1998 , 44, 942-7	9.4	65
172	The use of antibodies against the IL-2 receptor in transplantation. <i>Current Opinion in Immunology</i> , 1998 , 10, 507-12	7.8	119
171	Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. <i>Nuclear Medicine and Biology</i> , 1998 , 25, 89-93	2.1	37
170	Interleukin-2, interleukin-15, and their receptors. <i>International Reviews of Immunology</i> , 1998 , 16, 205-26	4.6	174
169	Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FIICE. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 14308-13	11.5	71
168	Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 2452-7	11.5	150
167	Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 1752-7	11.5	20
166	Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 3845-50	11.5	110
165	Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 13134-9	11.5	124

164	Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 13897-902	11.5	243
163	Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 14444-9	11.5	163
162	Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. <i>Virology</i> , 1997 , 237, 209-16	3.6	16
161	Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. <i>International Journal of Cancer</i> , 1997 , 70, 221-9	7.5	36
160	IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. <i>Immunity</i> , 1996 , 4, 329-36	32.3	397
159	Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotropic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 2897-902	11.5	191
158	IL-15: the role of translational regulation in their expression. <i>Journal of Leukocyte Biology</i> , 1996 , 59, 476-80	8.9	49
157	Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. <i>Journal of Experimental Medicine</i> , 1996 , 183, 1587-602	16.6	60
156	The metabolism branch: an exemplar of patient-oriented research. <i>Cancer Investigation</i> , 1995 , 13, 662-3	2.1	
155	Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 3137-41	11.5	95
154	Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. <i>Cancer</i> , 1995 , 75, 1598-607	6.4	30
153	Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 3344-7	11.5	27
152	The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 4940-4	11.5	362
151	A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 4935-9	11.5	337
150	The IL-2/IL-2 receptor system: a target for rational immune intervention. <i>Trends in Pharmacological Sciences</i> , 1993 , 14, 159-64	13.2	15
149	The interleukin-2 receptor: a target for immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 1993 , 685, 603-10	6.5	6
148	The IL-2/IL-2 receptor system: a target for rational immune intervention. <i>Trends in Immunology</i> , 1993 , 14, 264-70		162
147	Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection. <i>Annual Review of Immunology</i> , 1992 , 10, 675-704	34.7	36

146	The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 2165-9	11.5	45
145	Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor. <i>Transplantation</i> , 1992 , 54, 963-8	1.8	9
144	The multichain interleukin-2 receptor: a target for immunotherapy. <i>Annals of Internal Medicine</i> , 1992 , 116, 148-60	8	76
143	The interleukin-2 receptor: a target for immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 1992 , 323, 57-66	3.6	5
142	A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. <i>Transplantation</i> , 1991 , 51, 107-13	1.8	130
141	T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 1996-2000	11.5	183
140	Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis. <i>Journal of Cellular Biochemistry</i> , 1991 , 46, 302-11	4.7	90
139	Monoclonal antibodies in diagnosis and therapy. <i>Science</i> , 1991 , 252, 1657-62	33.3	298
138	Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency. <i>Clinical Immunology and Immunopathology</i> , 1991 , 61, S37-46		5
137	Adult T-cell Leukemia: Prospects for Immunotherapy 1991 , 319-334		
136	Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation. <i>Transplantation</i> , 1990 , 50, 760-5	1.8	14
135	Human B lymphocytes express the p75 component of the interleukin 2 receptor. <i>Leukemia Research</i> , 1990 , 14, 263-71	2.7	23
134	Lymphokine receptor-directed therapy: a model of immune intervention. <i>Journal of Clinical Immunology</i> , 1990 , 10, 19S-28S; discussion 28S-29S	5.7	6
133	Organization of the Human Immune System. <i>Dermatologic Clinics</i> , 1990 , 8, 593-607	4.2	
132	The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 8291-5	11.5	72
131	Association of intercellular adhesion molecule 1 with the multichain high-affinity interleukin 2 receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 7329-33	11.5	60
130	Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene. <i>Journal of the National Cancer Institute</i> , 1990 , 82, 1050-4	9.7	78
129	Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. <i>Lancet, The</i> , 1990 , 335, 497-500	40	138

128	Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. <i>Journal of Clinical Investigation</i> , 1990 , 86, 2093-8	15.9	81
127	Demonstration of delta rec-pseudo J alpha rearrangement with deletion of the delta locus in a human stem-cell leukemia. <i>Journal of Experimental Medicine</i> , 1989 , 170, 339-42	16.6	17
126	Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma. <i>Journal of the National Cancer Institute</i> , 1989 , 81, 914-23	9.7	62
125	Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody. <i>Transplantation</i> , 1989 , 48, 415-20	1.8	15
124	Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease. <i>New England Journal of Medicine</i> , 1989 , 321, 370-4	59.2	90
123	A T-cell line with an unusual phenotype. <i>Cancer</i> , 1989 , 64, 1859-66	6.4	
122	A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. <i>Nature</i> , 1989 , 339, 394-7	50.4	397
121	The multi-subunit interleukin-2 receptor. <i>Annual Review of Biochemistry</i> , 1989 , 58, 875-911	29.1	294
120	The interaction of interleukin 2 with its receptor in the generation of suppressor T cells in antigen-specific and antigen-nonspecific systems in vitro. <i>Clinical Immunology and Immunopathology</i> , 1989 , 52, 447-59		11
119	1988 Presidential address of the Clinical Immunology Society: clinical immunology is everywhere and nowhere--strength or weakness?. <i>Clinical Immunology and Immunopathology</i> , 1989 , 51, 2-12		3
118	Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 2878-82	11.5	84
117	Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. <i>Transplantation</i> , 1989 , 47, 55-9	1.8	58
116	Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 2031-5	11.5	228
115	A humanized antibody that binds to the interleukin 2 receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 10029-33	11.5	531
114	The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 10128-32	11.5	294
113	The Multichain Interleukin-2-Receptor: A Target for Immunotherapy of Patients with Adult T-cell Leukemia, Autoimmune Disorders and Individuals Receiving Allografts 1989 , 145-157		
112	The Multichain Interleukin-2 Receptor: From the Gene to the Bedside 1989 , 675-683		
111	Disorders of IL-2 Receptor Expression in HTLV-IAssociated Adult T Cell Leukemia 1989 , 126-141		

110	Isospora belli enteric infection in patients with human T-cell leukemia virus type I-associated adult T-cell leukemia. <i>American Journal of Medicine</i> , 1988 , 85, 435-8	2.4	22
109	Evidence for Distinct IL-2 Receptors in Induction versus Maintenance of LAK Function. <i>Annals of the New York Academy of Sciences</i> , 1988 , 532, 480-481	6.5	3
108	The multichain interleukin-2-receptor: A target for immunotherapy of patients with adult T-cell leukemia, autoimmune disorders and individuals receiving allografts. <i>Journal of Autoimmunity</i> , 1988 , 1, 641-653	15.5	4
107	Immunoglobulin and T cell antigen receptor gene arrangements indicate that the immune response in autoimmune thyroid disease is polyclonal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988 , 66, 958-63	5.6	14
106	Juxtaposition of the T-cell receptor alpha-chain locus (14q11) and a region (14q32) of potential importance in leukemogenesis by a 14;14 translocation in a patient with T-cell chronic lymphocytic leukemia and ataxia-telangiectasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988 , 85, 9287-91	11.5	49
105	Blockade of the interleukin-2 receptor by anti-Tac antibody inhibits the generation of antigen-nonspecific suppressor T cells in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988 , 85, 6478-82	11.5	9
104	Polyclonal nature of the intestinal mucosal lymphocyte populations in inflammatory bowel disease. A molecular genetic evaluation of the immunoglobulin and T-cell antigen receptors. <i>Gastroenterology</i> , 1988 , 95, 364-70	13.3	41
103	Normalization of antibody responsiveness in a patient with common variable hypogammaglobulinemia and HIV infection. <i>New England Journal of Medicine</i> , 1987 , 317, 1516-20	59.2	33
102	The arrangement of immunoglobulin and T cell receptor genes in human lymphoproliferative disorders. <i>Advances in Immunology</i> , 1987 , 40, 247-321	5.6	97
101	Deletional rearrangement in the human T-cell receptor alpha-chain locus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987 , 84, 8608-12	11.5	54
100	The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987 , 84, 5394-8	11.5	183
99	Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987 , 84, 4215-8	11.5	92
98	Flow cytometric resonance energy transfer measurements support the association of a 95-kDa peptide termed T27 with the 55-kDa Tac peptide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987 , 84, 7246-50	11.5	92
97	Type I and II insulin-like growth factor receptors on human phytohemagglutinin-activated T lymphocytes. <i>Cellular Immunology</i> , 1987 , 109, 318-31	4.4	63
96	The interleukin-2 receptor on normal and malignant lymphocytes. <i>Advances in Experimental Medicine and Biology</i> , 1987 , 213, 129-37	3.6	7
95	Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986 , 83, 474-8	11.5	154
94	Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986 , 83, 9694-8	11.5	377
93	Immunoglobulin and T-cell receptor gene rearrangement and expression in human lymphoid leukemia cells at different stages of maturation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986 , 83, 8759-63	11.5	69

92	Only high-affinity receptors for interleukin 2 mediate internalization of ligand. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986 , 83, 1463-6	11.5	147
91	Advances in diagnosis of hematologic malignancies. <i>Hospital Practice (1995)</i> , 1986 , 21, 69-77	2.2	1
90	Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science. <i>Trends in Biotechnology</i> , 1986 , 4, 259-264	15.1	43
89	The interleukin-2 receptor on malignant cells: a target for diagnosis and therapy. <i>Cellular Immunology</i> , 1986 , 99, 53-60	4.4	16
88	Evidence for a defect in "switch" T cells in patients with immunodeficiency and hyperimmunoglobulinemia M. <i>New England Journal of Medicine</i> , 1986 , 314, 409-13	59.2	114
87	The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. <i>Science</i> , 1986 , 232, 727-32	33.3	420
86	Immunodeficiency: immunoregulation and immunogenetics. <i>Clinical Immunology and Immunopathology</i> , 1986 , 40, 25-36		6
85	A pre-translational defect in a case of human mu heavy chain disease. <i>Molecular Immunology</i> , 1986 , 23, 725-32	4.3	7
84	The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. <i>Annals of Internal Medicine</i> , 1986 , 105, 560-72	8	141
83	Role and Molecular Biology of the Interleukin-2/Interleukin-2 Receptor System in Health and Disease 1986 , 553-562		1
82	Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985 , 82, 4230-4	11.5	236
81	Rearrangements of genes for the antigen receptor on T cells as markers of lineage and clonality in human lymphoid neoplasms. <i>New England Journal of Medicine</i> , 1985 , 313, 776-83	59.2	295
80	Methods for the study of the metabolism of immunoglobulins. <i>Methods in Enzymology</i> , 1985 , 116, 201-10	0.7	2
79	Human gamma-chain genes are rearranged in leukaemic T cells and map to the short arm of chromosome 7. <i>Nature</i> , 1985 , 316, 549-52	50.4	195
78	Activators of protein kinase C and 5-azacytidine induce IL-2 receptor expression on human T lymphocytes. <i>Journal of Cellular Biochemistry</i> , 1985 , 27, 267-76	4.7	21
77	NIH conference. Molecular genetic analysis of human lymphoid neoplasms. Immunoglobulin genes and the c-myc oncogene. <i>Annals of Internal Medicine</i> , 1985 , 102, 497-510	8	64
76	Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. <i>New England Journal of Medicine</i> , 1985 , 313, 79-84	59.2	681
75	Molecular Analysis of the Human Interleukin-2 Receptor 1985 , 8-20		

74 Interleukin-2 Receptors **1985**, 285-300

73 Molecular Cloning and Expression of cDNAs Encoding the Human Interleukin-2 Receptor **1985**, 185-195

72 Expression of interleukin 2 receptors on activated human B cells. *Journal of Experimental Medicine*, **1984**, 160, 1450-66 16.6 429

71 Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. *Nature*, **1984**, 311, 626-31 50.4 831

70 Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. *Nature*, **1984**, 312, 641-3 50.4 314

69 Immunoglobulin genes: rearrangement and translocation in human lymphoid malignancy. *Journal of Clinical Immunology*, **1984**, 4, 1-11 5.7 45

68 Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. *Proceedings of the National Academy of Sciences of the United States of America*, **1984**, 81, 5214-8 11.5 514

67 Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative hairy leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. *Journal of Clinical Investigation*, **1984**, 73, 1711-8 15.9 177

66 Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. *Journal of Clinical Investigation*, **1984**, 74, 966-71 15.9 70

65 NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. *Annals of Internal Medicine*, **1984**, 100, 543-57 8 124

64 A Monoclonal Antibody to the Human Receptor for T Cell Growth Factor **1984**, 43-66 2

63 Genetic Rearrangements of Human Immunoglobulin Genes **1984**, 75-95 1

62 Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. *New England Journal of Medicine*, **1983**, 309, 1593-9 59.2 514

61 Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors. *New England Journal of Medicine*, **1983**, 309, 826-31 59.2 168

60 Characterization of the human receptor for T-cell growth factor. *Proceedings of the National Academy of Sciences of the United States of America*, **1983**, 80, 6957-61 11.5 201

59 Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **1983**, 80, 4522-6 11.5 276

58 Variable amplification of immunoglobulin lambda light-chain genes in human populations. *Nature*, **1983**, 304, 172-4 50.4 126

57 The proportion of TA, TG, and TM cells in various immunodeficiency and autoimmune disorders. *Cellular Immunology*, **1983**, 80, 105-14 4.4 1

56	Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia. <i>Journal of Clinical Investigation</i> , 1983 , 71, 282-95	15.9	69
55	Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. <i>Journal of Clinical Investigation</i> , 1983 , 71, 301-13	15.9	433
54	Ataxia-telangiectasis: a multisystem hereditary disease with immunodeficiency, impaired organ maturation, x-ray hypersensitivity, and a high incidence of neoplasia. <i>Annals of Internal Medicine</i> , 1983 , 99, 367-79	8	78
53	Normal human B cells display ordered light chain gene rearrangements and deletions. <i>Journal of Experimental Medicine</i> , 1982 , 156, 975-85	16.6	104
52	B cell, helper T cell, and suppressor T cell abnormalities contribute to disordered immunoglobulin synthesis in patients following bone marrow transplantation. <i>Transplantation</i> , 1982 , 33, 184-90	1.8	46
51	Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. <i>Advances in Immunology</i> , 1982 , 32, 1-63	5.6	138
50	A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. <i>Nature</i> , 1982 , 300, 267-9	50.4	795
49	Successful treatment with acyclovir of an immunodeficient patient infected simultaneously with multiple herpesviruses. <i>American Journal of Medicine</i> , 1981 , 70, 882-6	2.4	31
48	Human immunoglobulin kappa light-chain genes are deleted or rearranged in lambda-producing B cells. <i>Nature</i> , 1981 , 290, 368-72	50.4	314
47	Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. <i>Cell</i> , 1981 , 27, 583-91	56.2	844
46	Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. <i>Gastroenterology</i> , 1981 , 80, 166-168	13.3	34
45	Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1981 , 78, 7096-100	11.5	401
44	Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. <i>Cancer</i> , 1981 , 47, 328-32	6.4	48
43	Clustered arrangement of immunoglobulin lambda constant region genes in man. <i>Nature</i> , 1981 , 294, 536-40	50.4	338
42	Human immunoglobulin D segments encoded in tandem multigenic families. <i>Nature</i> , 1981 , 294, 631-5	50.4	218
41	Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells. <i>New England Journal of Medicine</i> , 1981 , 304, 1382-7	59.2	33
40	Characterization of a soluble suppressor of human B cell immunoglobulin biosynthesis produced by a continuous human suppressor T cell line. <i>Journal of Experimental Medicine</i> , 1981 , 154, 156-67	16.6	22
39	In vitro generation of antigen-specific hemolytic plaque-forming cells from human peripheral blood mononuclear cells. <i>Journal of Experimental Medicine</i> , 1981 , 154, 1069-84	16.6	36

38	Prospective evaluation of some candidate tumor markers in the diagnosis of pancreatic cancer. <i>Digestive Diseases and Sciences</i> , 1980 , 25, 161-72	4	22
37	Neoplasms of immunoregulatory T cells in clinical investigation. <i>Journal of Investigative Dermatology</i> , 1980 , 74, 267-71	4.3	7
36	Characteristics of Multiple Myeloma as an Immunodeficiency Disease 1980 , 151-169		6
35	X-linked hypogammaglobulinemia and isolated growth hormone deficiency. <i>New England Journal of Medicine</i> , 1980 , 302, 1429-34	59.2	161
34	Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30). <i>Journal of Experimental Medicine</i> , 1980 , 151, 257-62	16.6	37
33	Separation of human blood monocytes and lymphocytes on a continuous Percoll gradient. <i>Journal of Immunological Methods</i> , 1980 , 33, 1-9	2.5	153
32	Disorders of Suppressor T Cells in Immunodeficiency and Malignancy 1980 , 381-402		
31	Polyclonal activation of human B lymphocytes by Nocardia water soluble mitogen (NWSM). <i>Immunological Reviews</i> , 1979 , 45, 69-92	11.3	47
30	Testicular germ-cell neoplasms: recent advances in diagnosis and therapy. <i>Annals of Internal Medicine</i> , 1979 , 90, 373-85	8	91
29	Corticosteroid-responsive intestinal lymphangiectasia secondary to an inflammatory process. <i>New England Journal of Medicine</i> , 1979 , 300, 605-6	59.2	41
28	T Cell Disorders in Primary Immunodeficiency Diseases 1979 , 5-30		3
27	T-T INTERACTIONS IN THE GENERATION OF HUMAN SUPPRESSOR EFFECTOR CELLS IN VITRO 1979 , 69-84		
26	T cell disorders in primary immunodeficiency diseases. <i>Seminars in Immunopathology</i> , 1978 , 1, 239-264		9
25	Fc IgM receptors on human lymphoblastoid B cell lines. <i>European Journal of Immunology</i> , 1978 , 8, 274-8	6.1	8
24	The suppressor-cell network in cancer (first of two parts). <i>New England Journal of Medicine</i> , 1978 , 299, 1281-4	59.2	131
23	The suppressor-cell network in cancer (second of two parts). <i>New England Journal of Medicine</i> , 1978 , 299, 1335-41	59.2	77
22	Characterization of a suppressor-cell leukemia. Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells. <i>New England Journal of Medicine</i> , 1978 , 298, 66-72	59.2	132
21	Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. <i>Annals of Internal Medicine</i> , 1978 , 88, 226-38	8	201

20	The role of the radioimmunoassay of serum alpha-fetoprotein and human chorionic gonadotropin in the intensive chemotherapy and surgery of metastatic testicular tumors. <i>Journal of Urology</i> , 1978 , 119, 759-62	2.5	30
19	Suppressor cells in neoplastic disease. <i>Journal of the National Cancer Institute</i> , 1978 , 61, 5-11	9.7	86
18	The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. <i>Journal of Urology</i> , 1977 , 118, 994-9	2.5	140
17	Alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors. <i>Journal of Urology</i> , 1977 , 118, 593-6	2.5	24
16	Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique. <i>Cancer</i> , 1977 , 40, 2136-51	6.4	208
15	Metabolism of Immunoglobulins. <i>Clinical Immunobiology</i> , 1976 , 71-95		4
14	The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. <i>Cancer</i> , 1976 , 37, 215-9	6.4	90
13	Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. <i>New England Journal of Medicine</i> , 1976 , 295, 1237-40	59.2	118
12	Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. <i>New England Journal of Medicine</i> , 1975 , 293, 887-92	59.2	375
11	The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. <i>Cancer</i> , 1974 , 34, suppl:1510-5	6.4	175
10	Discordance of human chorionic gonadotropin and alpha-fetoprotein in testicular teratocarcinomas. <i>Cancer</i> , 1973 , 31, 1065-8	6.4	109
9	Impaired lymphocyte transformation in intestinal lymphangiectasia: evidence for at least two functionally distinct lymphocyte populations in man. <i>Journal of Clinical Investigation</i> , 1972 , 51, 1319-25	15.9	62
8	The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. <i>Journal of Clinical Investigation</i> , 1972 , 51, 2916-27	15.9	215
7	Immunodeficiency Disease and Malignancy. <i>Annals of Internal Medicine</i> , 1972 , 77, 605	8	156
6	Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. <i>Journal of Clinical Investigation</i> , 1971 , 50, 2331-8	15.9	72
5	Anaphylactic reactions to IgA: a difficult transfusion problem. <i>American Journal of Clinical Pathology</i> , 1970 , 54, 618-21	1.9	54
4	The erythropoiesis-stimulating factors produced by tumors. <i>Annals of the New York Academy of Sciences</i> , 1968 , 149, 509-15	6.5	43
3	The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. <i>Journal of Experimental Medicine</i> , 1967 , 126, 207-21	16.6	249

2 The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor. *American Journal of Medicine*, **1961**, 31, 318-24

2.4 101

1 Immune Regulation 33-44